IN THIS PRACTICE

Litigation

In The News

    • February 1, 2012
      'Fresh from the biotech pipeline ? 2011'
      Nature Biotechnology
      D. Christopher Ohly
      This article about the U.S. FDA approval process for biosimilar drugs quotes Schiff Hardin partner Chris Ohly. Mr. Ohly, who focuses on pharmaceuticals in the firm's Intellectual Property Group, comments that companies moving through the biosimilar and interchangeable drug approval process may end up innovating their products as a result.
    • April 25, 2011
      "Patents on the line"
      BioCentury
      D. Christopher Ohly
      In this article about challenges in the Supreme Court to patent protections, Schiff Hardin partner Chris Ohly is quoted regarding the standards used to invalidate a patent.
    • February 11, 2011
      "Patent reform looks likely to pass this year"
      BioPharm Insight
      D. Christopher Ohly
      Schiff Hardin's Christopher Ohly, a partner in the firm's Intellectual Property group, is quoted in this pharmaceutical news service story on patent reform legislation. Mr. Ohly points out likely consequences of the legislation, including the significant change to first-to-file priority in patent applications.
  • Print
  • Text SizeSmall Larger

© 2012 Schiff Hardin LLP
Schiff Hardin LLP is a general practice law firm representing clients across the United States and around the world. We have offices located in Ann Arbor, Atlanta, Boston, Chicago, Lake Forest, New York, San Francisco and Washington. Our attorneys are strong advocates and trusted advisers — roles that contribute to many lasting client relationships.